Proposed section structure
This topic is best organized around the clinical problem of biochemical surveillance after thyroid cancer treatment, the analytical issue of antibody interference, the retrospective cohort design, the prognostic results, and the implications for laboratory interpretation and follow-up strategy. The article therefore uses the following structure: Highlights; Clinical background and unmet need; Study design and methods; Key results; Clinical interpretation; Strengths and limitations; Practice implications; Conclusion; Funding and trial registration; References.
Highlights
Low-level postoperative antithyroglobulin antibody positivity, defined by the assay-specific limit of quantification rather than the conventional reference cutoff, identified a subgroup of papillary thyroid carcinoma patients at higher recurrence risk despite undetectable unstimulated thyroglobulin after radioactive iodine treatment.
Among 1039 patients followed for a median of 12.0 years, 10-year progression-free survival declined stepwise from 97.9% in those with undetectable TgAb to 94.6% in those with borderline TgAb and 88.5% in those with elevated TgAb.
In multivariable analysis, the borderline TgAb group had approximately double the recurrence risk versus the undetectable group (adjusted hazard ratio 2.01, confidence interval 1.03-3.96; p = 0.043), suggesting clinically meaningful information exists below the traditional positivity threshold.
Within the borderline group, persistent borderline TgAb over time was unfavorable: patients whose TgAb failed to become undetectable had a recurrence rate of 12.9%, whereas TgAb became undetectable in 75.0% over 6.3 years.
Clinical background and unmet need
Serum thyroglobulin is central to postoperative surveillance in differentiated thyroid cancer, particularly after total thyroidectomy and radioactive iodine ablation, when any measurable Tg may indicate residual or recurrent thyroid tissue. In papillary thyroid carcinoma, an undetectable unstimulated Tg at 6 to 12 months after initial therapy is generally reassuring and often supports a favorable response classification. The challenge is that Tg is not an infallible biomarker. Antithyroglobulin antibodies can interfere with Tg measurement, typically causing falsely low or occasionally unreliable results in immunometric assays. This makes interpretation of an “undetectable” Tg more complex in TgAb-positive patients.
Current practice usually classifies TgAb according to the manufacturer’s reference range cutoff, but that threshold was not necessarily designed to detect clinically relevant assay interference. The limit of quantification, by contrast, reflects the lowest concentration at which the assay can measure the analyte with acceptable analytical performance. The key question addressed by Kim and colleagues is clinically important: if TgAb is detectable above the assay’s LOQ but still below the conventional reference limit, does that “borderline” level identify patients whose undetectable Tg may be less trustworthy and whose recurrence risk is actually higher?
This issue matters because thyroid cancer follow-up increasingly depends on nuanced biochemical risk stratification. A large group of patients are categorized as low risk or excellent responders, but even within this broad category there is residual heterogeneity. A marker that refines surveillance intensity without requiring invasive testing would be useful, especially if it draws on laboratory data already being collected in routine care.
Study design and methods
Design and population
This was a retrospective cohort study of 1039 patients with papillary thyroid carcinoma measuring at least 1 cm who underwent total thyroidectomy followed by radioactive iodine ablation between 2009 and 2012. All patients had undetectable unstimulated serum Tg, defined as less than 0.2 ng/mL, at 6 to 12 months after treatment. Simultaneously measured TgAb levels were available for classification.
The cohort had a median age of 48.2 years; 18.1% were male. Median tumor size was 1.5 cm, and lymph node metastases were present in 67.8%, indicating that many patients were not trivially low risk by anatomic criteria even though they had excellent early biochemical response by Tg.
Exposure classification
The investigators classified postoperative TgAb using two analytical thresholds from the same assay: the conventional reference limit of 60.0 U/mL and the assay-specific limit of quantification of 43.4 U/mL. This generated three groups:
Undetectable: less than 43.4 U/mL
E borderline: 43.4-60.0 U/mL
Elevated: greater than 60.0 U/mL
This framework is the conceptual core of the paper. It separates truly undetectable TgAb from analytically detectable but conventionally “negative” TgAb.
Outcome
The primary clinical endpoint was recurrence during follow-up. The authors reported progression-free survival over a median follow-up of 12.0 years, a major strength given the often indolent time course of papillary thyroid carcinoma.
Key results
Distribution of TgAb categories
Using the LOQ-informed classification, 65.6% of patients had undetectable TgAb, 23.5% had borderline TgAb, and 10.9% had elevated TgAb. In practical terms, nearly one in four patients fell into the newly highlighted borderline category that would likely receive less attention if only the traditional reference cutoff were used.
Recurrence risk by initial TgAb status
Overall recurrence occurred in 4.8% of the cohort. However, recurrence was not evenly distributed across TgAb strata. The 10-year progression-free survival rates were:
97.9% in the undetectable TgAb group
94.6% in the borderline TgAb group
88.5% in the elevated TgAb group
The between-group difference was statistically significant (p < 0.001), and the pattern suggests a graded biological signal rather than a simple binary effect. Even among patients with undetectable unstimulated Tg after initial treatment, those with detectable TgAb above the LOQ had worse long-term outcomes.
Multivariable analysis
The multivariable model showed that the borderline group had a significantly higher recurrence risk than the undetectable group, with an adjusted hazard ratio of 2.01 (confidence interval 1.03-3.96; p = 0.043). This finding is especially noteworthy because the borderline group sits below the conventional positivity threshold. The data therefore argue that analytically detectable TgAb can carry prognostic information independent of overt antibody elevation.
The abstract does not provide the full covariate list used in adjustment, but the adjusted result supports the view that this association was not explained solely by baseline clinicopathologic differences.
Trajectory of borderline TgAb over time
Static biomarker levels are useful, but longitudinal trends are often more clinically informative in thyroid cancer follow-up. In the borderline TgAb group, TgAb became undetectable in 75.0% of patients over 6.3 years. That is reassuring and suggests many borderline results may represent a resolving postoperative immune signal or diminishing residual thyroid antigen exposure.
However, patients whose TgAb remained persistently borderline had a recurrence rate of 12.9% (p = 0.01), indicating that persistence of low-level detectability matters. This dynamic aspect strengthens the biological plausibility of the study. It is not merely the presence of a marginal antibody signal at one time point, but its failure to clear over time, that appears particularly concerning.
Clinical interpretation
Why the LOQ may matter more than the reference limit
The study draws attention to a laboratory concept with direct clinical consequences. A reference limit is designed to distinguish values seen in a healthy or comparator population from abnormal values. The LOQ, in contrast, reflects what the assay can reliably measure. For a marker like TgAb, whose importance lies partly in whether it can interfere with another assay, detectability itself may be more relevant than whether the concentration exceeds a population-based abnormality threshold.
That distinction is easy to overlook in routine oncology and endocrinology practice. A TgAb result reported as “within normal range” may still be high enough to indicate possible Tg interference if it is above the LOQ. This paper suggests that such low-level detectability is not analytically trivial and may identify patients who deserve closer biochemical and imaging surveillance.
How this fits with current thyroid cancer monitoring paradigms
The 2015 American Thyroid Association guideline recognizes TgAb as an important confounder in Tg measurement and recommends following TgAb trends in the same assay over time. The present study refines that principle by suggesting that clinically relevant TgAb positivity begins at the assay’s quantifiable range, not just above the manufacturer’s upper reference limit.
For clinicians, the practical implication is not that every borderline TgAb result should trigger alarm, but that these patients may not belong in the same reassurance category as those with completely undetectable TgAb. In an otherwise low-risk patient with undetectable Tg and borderline TgAb, one might reasonably maintain trend-based surveillance rather than rapidly de-escalating follow-up. Persistent borderline or rising TgAb could justify more careful neck ultrasound review, repeat laboratory assessment in the same platform, and a lower threshold for further evaluation.
Biological plausibility
TgAb may function both as a marker of assay interference and as an indirect marker of persistent thyroid antigen exposure from residual normal thyroid tissue or cancer. After total thyroidectomy and radioactive iodine ablation, TgAb levels often decline gradually over months to years if there is no ongoing antigenic source. Persistent or rising TgAb has long been viewed as suspicious for persistent or recurrent disease, even when Tg remains low or undetectable. This study is consistent with that biology and extends it into the low-level range detectable by assay sensitivity but below classic antibody positivity.
Strengths and limitations
Strengths
The study has several notable strengths. First, the sample size was large for a single thyroid cancer surveillance cohort. Second, follow-up was long, with a median of 12.0 years, which is essential in papillary thyroid carcinoma where recurrence may be delayed. Third, the cohort was clinically focused and homogeneous in a useful way: all patients underwent total thyroidectomy and radioactive iodine treatment and all had undetectable unstimulated Tg at the landmark 6- to 12-month evaluation. This makes the prognostic signal of TgAb easier to interpret. Fourth, the study addresses a real-world laboratory issue with direct applicability to postoperative monitoring.
Limitations
The study is retrospective, so residual confounding and selection bias cannot be excluded. The findings are also assay-specific. The reported LOQ of 43.4 U/mL and reference limit of 60.0 U/mL are tied to the analytical platform used in this cohort; these exact cut points cannot be generalized automatically across laboratories. This is a critical point for translation to practice. The message is likely transferable, but the threshold itself may not be.
Because the study included only patients treated with radioactive iodine after total thyroidectomy, applicability to patients managed without RAI, to microcarcinoma, or to other differentiated thyroid cancer subtypes may be limited. The abstract also does not detail recurrence definitions, site distribution of recurrence, serial imaging protocols, or the full adjusted model. Those details will matter when clinicians judge how much incremental value LOQ-based TgAb classification adds beyond traditional clinicopathologic risk factors and dynamic risk stratification.
Finally, the overall recurrence rate was low, which is expected in this setting and clinically reassuring, but it also means absolute risk differences are modest even when relative hazards are meaningful. This is an important nuance when counseling patients.
Practice implications
This study should prompt endocrinologists, oncologists, and laboratory physicians to revisit how TgAb results are reported and interpreted in thyroid cancer follow-up. At minimum, clinicians should know whether TgAb is detectable above the assay’s LOQ, even if the value is below the laboratory’s usual reference cutoff. Laboratories may consider displaying both the reference interval and the LOQ, or adding interpretive comments for thyroid cancer surveillance when analytically detectable TgAb is present.
For clinicians, three practical messages emerge. First, an undetectable Tg is most reassuring when TgAb is also undetectable rather than merely “normal.” Second, patients with borderline TgAb may merit longitudinal trend monitoring instead of immediate de-escalation. Third, persistent borderline TgAb appears more concerning than transient borderline detectability.
This does not mean management should be driven by TgAb alone. Neck ultrasound findings, pathology, initial extent of disease, and the direction of biomarker change remain essential. Still, the study suggests that an analytically informed reading of TgAb can improve risk discrimination in a common clinical scenario.
Conclusion
Kim and colleagues provide persuasive long-term evidence that in papillary thyroid carcinoma patients with undetectable unstimulated thyroglobulin after thyroidectomy and radioactive iodine ablation, antithyroglobulin antibodies detectable above the assay’s limit of quantification carry prognostic value. Patients in the borderline TgAb range, between the LOQ and the conventional reference limit, had significantly worse progression-free survival and a roughly twofold higher adjusted recurrence risk than patients with undetectable TgAb. Persistent borderline detectability over time further enriched recurrence risk.
The broader lesson is that analytical sensitivity matters in cancer biomarker interpretation. For TgAb, the question may not simply be whether the value is above the laboratory’s abnormal range, but whether it is detectably present at all on a reliable assay. Before practice changes are standardized, external validation across platforms and settings is needed. Even so, this study offers a clinically useful refinement to postoperative surveillance in differentiated thyroid cancer and may help identify patients whose “undetectable Tg” deserves a more cautious reading.
Funding and trial registration
The abstract does not report a funding source. No ClinicalTrials.gov registration number is provided, which is expected for a retrospective observational cohort study.
References
1. Kim CA, Kim YI, Lee DY, Lee SH, Kim WB, Ryu JS, Kim WG, Kim TY, Jeon MJ. Prognostic Significance of Detectable Antithyroglobulin Antibodies Based on Analytical Sensitivity in Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin after Radioactive Iodine Treatment. Thyroid. 2026 Jun 1:10507256261457026. PMID: 42225640.
2. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133. doi:10.1089/thy.2015.0020.
3. Spencer C, Fatemi S. Thyroglobulin antibody (TgAb) methods — strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2013;27(5):701-712. doi:10.1016/j.beem.2013.07.003.
4. Kim WG, Kim TY, Kim EY, et al. Serum antithyroglobulin antibodies as a prognostic marker in patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93(12):4683-4689. doi:10.1210/jc.2008-1042.
5. Rosario PW, Mineiro Filho AF, Prates BS, Silva LC, Calsolari MR. Postablation antithyroglobulin antibodies as surrogate markers of disease activity in patients with differentiated thyroid carcinoma. Endocrine. 2012;42(1):191-195. doi:10.1007/s12020-012-9640-6.
